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USE OF RED CELL TRANSFUSION IN CHRONIC ANEMIA
Repeated transfusions or use of an erythropoiesis-stimulating
agent (ESA) are treatment options for chronic anemia in
CKD. The choice between these depends on their relative
benefits and harms, which vary among patients. For example,
patients with a previous stroke have the greatest absolute risk
of ESA-related stroke,127 whereas multiparous women have
the highest risk of allosensitization with transfusion.190,191
Although the clinical importance of allosensitization is
disputed, it may delay or reduce the possibility of future
kidney transplantation.
4.1.1: When managing chronic anemia, we recommend
avoiding, when possible, red cell transfusions to
minimize the general risks related to their use. (1B)
4.1.2: In patients eligible for organ transplantation, we
specifically recommend avoiding, when possible, red
cell transfusions to minimize the risk of allosensi-
tization. (1C)
4.1.3: When managing chronic anemia, we suggest that the
benefits of red cell transfusions may outweigh the
risks in patients in whom (2C):
K ESA therapy is ineffective (e.g., hemoglobino-
pathies, bone marrow failure, ESA resistance)
K The risks of ESA therapy may outweigh its
benefits (e.g., previous or current malignancy,
previous stroke)
4.1.4: We suggest that the decision to transfuse a CKD
patient with non-acute anemia should not be based
on any arbitrary Hb threshold, but should be
determined by the occurrence of symptoms caused
by anemia. (2C)
RATIONALE
As with any treatment, the use of red cell transfusions should
be considered in terms of the balance of benefit and harms.
The primary benefit is in maintaining sufficient oxygen-
carrying capacity and improvement in anemia-related
symptoms.192 The harms are summarized in Tables 5 and 6
and discussed further below. This balance must also be
considered alongside the balance between the benefits and
harms of ESA therapy which is an alternative treatment for
the anemia of CKD. The benefits and harms of ESA therapy
are discussed in detail in Chapter 3, but, in summary, the
benefits include improvement in anemia-related symptoms
and reduced need for transfusion, and the most important
harms are increased risk of stroke, thromboembolic events,
and cancer progression or recurrence. When choosing
between these two treatments for anemia in an individual,
patient characteristics which influence the balance between
benefits and harms for each treatment should be considered.
These include history of stroke and previous or current
cancer which place patients receiving ESA therapy at much
higher absolute risk of these two problems. Conversely,
patients potentially eligible for kidney transplantation have
the greatest potential harm from transfusion, in terms of
allosensitization,191,193,194 although the clinical importance of
allosensitization is disputed. Previously transplanted patients
and multiparous women seem to have the greatest absolute
risk of allosensitization.190,191
A related issue is when should the decision to treat a
patient with either an ESA or a transfusion be made? This
decision is subtly different for the two types of treatment as
ESAs may be used to avoid transfusion and therefore before
the need for transfusion has arisen i.e., in a prophylactic sense.
Furthermore, the magnitude of the potential harms of
transfusion (e.g., from infection) and some of the benefits
from ESAs (e.g., transfusion avoidance) is dependent on the
threshold for transfusion. If that threshold is high (i.e.,
transfusion is reserved until symptoms become severe or the
Hb reaches a very low level) the risks related to transfusion
will be low and the benefit of ESA therapy in avoiding
transfusions will be small. Unfortunately, there is no
consensus about when transfusion is indicated although we
do know that the rate of transfusion increases markedly
when the Hb falls below 10 g/dl (100 g/l);122,127 whether that
simply reflects practice-patterns or represents clear clinical
need is uncertain. The following trials give examples of
transfusion rates in CKD 5D and CKD ND patients. The trial
conducted by the Canadian Erythropoietin Study Group,
published in 1990, enrolled 118 CKD 5HD patients Hb
o9.0 g/dl (o90 g/l), 49 (42%) of whom were described as
‘transfusion-dependent’.122 The patients averaged approxi-
mately 7 transfusions each in the previous 12 months. These
patients were randomized, equally, to 6 months treatment
with placebo, erythropoietin with a target Hb 9.5–11.0 g/dl
(95–110 g/l), or erythropoietin with a target Hb 11.5–13.0 g/dl
(115–130 g/l). After 8 weeks, 23 patients in the placebo group
received a blood-transfusion, compared with one in each
of the two erythropoietin groups (for a gastrointestinal
hemorrhage and following surgery). More recently, in the
Trial to Reduce Cardiovascular Events with Aranesp Therapy
(TREAT), published in 2009, 4038 patients with diabetes,
CKD ND and anemia (Hbr11.0 g/dl [r110 g/l]), were
randomized, equally, to darbepoetin-alfa with target Hb
13 g/dl (130 g/l) or to placebo, with ‘rescue’ darbepoetin-alfa
when Hb fell below 9.0 g/dl (90 g/l).127 Over a median follow-
up of 29 months, 297/2012 (15%) patients randomized to
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darbepoetin-alfa and 496/2026 (25%) assigned to placebo
received red cell transfusions (HR 0.56, 95% CI 0.49–0.65,
Po0.001).
We suggest that the decision to transfuse in the patient
with non-acute anemia related to CKD should not be based
upon any arbitrary Hb threshold and should, instead, be
determined by the occurrence of symptoms and signs caused
by anemia. We recognize that symptoms such as dyspnea and
fatigue are non-specific, and that anemia-related symptoms
may occur at different Hb levels in different patients.
Risks of blood transfusion
Risks associated with blood transfusion include transfusion
errors, volume overload, hyperkalemia, citrate toxicity
(leading to metabolic alkalosis and hypocalcemia), hypother-
mia, coagulopathy, immunologically-mediated transfusion
reactions, including transfusion-related acute lung injury
(TRALI), and iron overload, all of which are uncommon
(Table 5).190,195–207 Transmission of infections, although rare,
is a major concern and this risk varies between countries
(Table 6).208–211 These complications are reviewed extensively
elsewhere. The importance of human leukocyte antigen
(HLA) sensitization is disputed and discussed in more detail
below.
HLA sensitization. The risk of sensitization after blood
transfusion has changed over time probably, at least in part,
due to changes in blood transfusion practices and the use of
more precise methods to measure allosensitization.
In the early 1980s, Opelz et al. examined the risk of
sensitization in 737 CKD 5HD patients (Figures 3A and 3B),
of whom 331 were followed prospectively (Figure 3C).190
Approximately 90% of all transfusions were given in the form
of ‘packed cells’ and antibodies were measured by the
lymphocyte cytotoxicity test. Overall, 28% of patients
followed prospectively developed HLA antibodies. Of these,
18% developed reactivity to 10–50% of the panel, 7% to
50–90%, and o3% to 490% of the panel after up to 20
transfusions (Figure 3C). Among men, 90% remained
‘unresponsive’ (o10% antibody reactivity against the
panel) and 10% developed reactivity to 10–50% of the panel
(Figure 3C). In contrast, after 10 transfusions, only 60% of
the women were ‘unresponsive,’ 11% demonstrated 10–50%
reactivity, 23% 51–90% reactivity, and 6% 490% reactivity
(Figure 3C). These data suggested that the main drivers of
HLA sensitization following red cell transfusion are previous
pregnancies and previous transplantation. The data also
suggested that men have a much lower risk of HLA
sensitization following transfusion than women, and women
with multiple pregnancies have a much greater risk of HLA
sensitization than nulliparous women. However, more recent
data from the US Renal Data System (USRDS) 2010 Annual
Report,191 have challenged this assumption, suggesting that
males receiving previous blood transfusions may also be at
increased risk.
Studies performed in the last two decades showed that the
risk of sensitization with blood transfusion is apparently
lower than previously reported, with an overall response rate
ranging from 2 to 21%.216–218 A possible, albeit controversial,
explanation for this lower sensitization rate is that red cell
transfusions in recent years are less immunogenic because
they contain fewer leukocytes due to widespread use of blood
filters.
Other tentative conclusions from previous studies include
the following: a) washed-red cells do not appear to be less
immunogenic than non-washed red cells;190 b) no consistent
reduction in sensitization has been demonstrated with
donor-specific217 and HLA-DR matched transfusions;219 c)
higher numbers of blood transfusions have been associated
with an increased risk of sensitization in some studies220,221
but not in others.190,222
However, more recent data from the USRDS indicates that
risk of sensitization with blood transfusions is substantial.
For example, compared with patients who have never
received a blood transfusion, patients who received transfu-
sions have an odds ratio of having panel reactive antibody
(PRA)480% of 2.38.191 Interestingly, in this analysis the risk
of being highly sensitized at the time of transplantation was
higher for men than for women.
Effect of leukocyte-reduced blood transfusions on sensitiza-
tion. Although, leukocytes may be a contributor to, if not
the cause of, a number of adverse consequences of blood
transfusion, including immunologically-mediated effects,
Table 6 | Estimated risk of transfusion-related infections per
unit transfused
Potential transfusion-related risks Estimated risk*
Hepatitis B 1 in 282,000–1 in 357,000a
West Nile virus 1 in 350,000b
Death from bacterial sepsis 1 in 1,000,000b
Hepatitis C 1 in 1,149,000a
Human immunodeficiency virus (HIV) 1 in 1,467,000a
*United States data.
aData from Carson JL et al.212
bData from Rawn J.215
Table 5 | Estimated risk associated with blood transfusions
per unit transfused
Adverse event Estimated risk*
Immunological
Fever/allergic reactions 1 in 100–200a,b
Hemolytic reaction 1 in 6000b
Transfusion-related acute lung injury (TRALI) 1 in 12,350a
Anaphylaxis 1 in 50,000b
Fatal hemolysis 1 in 1,250,000a
Graft versus host disease (GVHD) Rare
Other
Mistransfusion 1 in 14,000–19,000c
*United States data.
aData from Carson JL et al.212
bData from Klein.213
cData from Klein HG et al.214
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infectious disease transmission, and reperfusion injury,
leukoreduction of blood products does not decrease sensi-
tization in previously transplanted or in potential future
kidney transplant candidates.223–225 One recent study re-
ported that male patients awaiting their first organ transplant
had a fourfold increased risk of developing HLA antibody if
they had been previously transfused when compared with
those who did not have a history of a transfusion.226 Thus,
Figure 3 | Lymphocytotoxic antibody reactivity against random donor test panel in relation to the number of blood transfusions.
Fractions of patients reacting against o10%, 10 to 50%, 51 to 90% and 490% of the panel donors are plotted. All 737 patients were on
chronic hemodialysis, waiting for a first kidney transplant. Numbers of patients after 2, 5, 10, 15, and 20 transfusions are indicated at top of
graphs. (A) Male and female patients. (B) Females patients separated by the number of previous pregnancies. (C) Lymphocytotoxic
antibodies in patients who were studied prospectively throughout the course of treatment. Reprinted from Opelz G, Graver B, Mickey MR
et al. Lymphocytotoxic antibody responses to transfusions in potential kidney transplant recipients. Transplantation 1981; 32(3): 177–183
(ref. 190) with permission from Lippincott Williams & Wilkins; accessed http://journals.lww.com/transplantjournal/Abstract/1981/09000/
Lymphocytoxic_Antibody_Responses_to_Transfusions.2.aspx
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transfusion in the post-leukodepletion era still continues to
pose a significant risk of sensitization. A possible reason for
this finding is that the number of HLA molecules contributed
by the red cells is comparable to that of leukocytes.227
Association between sensitization and delay in organ trans-
plantation. According to USRDS data reported in 2010, the
mean wait-time to transplant for patients listed between 1991
and 2008 was an average of 2 months longer for transfused
than non-transfused patients in the United States.191
Increased PRA titers, whether due to blood transfusions or
other factors, were associated with a longer wait to find a
compatible donor and may have completely precluded
transplantation in some patients. Non-sensitized patients
(0% PRA at the time of listing) had the shortest wait-time
(median of 2.5 years in 2005) while those with a PRA of
1–19% and 20–79% had median wait-times of 2.9 and 4.3
years, respectively. Highly sensitized patients (Z80% PRA)
waited the longest and in these patients a median wait-time
Table 7 | Indications for blood transfusions
Indication Comments
When rapid correction of anemia is required to
stabilize the patient’s condition (e.g., acute
hemorrhage, unstable myocardial ischemia)
K Red cell transfusion in patients with acute hemorrhage is indicated in the following
situations: a) rapid acute hemorrhage without immediate control of bleeding; b)
estimated blood loss 430–40% of blood volume (1500–2000ml) with symptoms of
severe blood loss; c) estimated blood losso25–30% blood volume with no evidence
of uncontrolled hemorrhage, if signs of hypovolemia recur despite colloid/crystalloid
resuscitation; d) in patients with co-morbid factors, transfusions may be necessary
with lesser degrees of blood loss.234
K Studies evaluating the importance of anemia and the role of transfusion in the setting
of an acute coronary syndrome (i.e., unstable angina, myocardial infarction) have
reached differing conclusions.
K The American College of Cardiology/American Heart Association and American
College of Chest Physicians guidelines do not make any recommendations
concerning the potential benefit or risk of blood transfusion in the setting of an acute
coronary syndrome.235,236 However, in a review of clinical trials of patients with a
non-ST elevation acute coronary syndrome, the risk of cardiovascular mortality,
nonfatal myocardial infarction, or recurrent ischemia at 30 days was significantly
higher in patients with a Hb concentration below 11 g/dl (110 g/l) than those
with a Hb Z11 g/dl (Z110 g/l).237
K Although anemia occurs frequently in patients with heart failure, limited data are
available on treatment of anemia in this population.
K Correction of anemia is not an evidence-based therapy in heart failure as noted in the
2006 Heart Failure Society of America guidelines, 2012 European Society of
Cardiology (ESC) guidelines, and 2009 American College of Cardiology/American
Heart Association guidelines.238–240
K Therefore, the general indications for red cell transfusion apply to patients with heart
failure; however, careful attention must be paid to volume status.
When rapid pre-operative Hb correction is required K Criteria have been proposed for perioperative transfusions.234 These are generally not
recommended when the Hb isZ10 g/dl (Z100 g/l) in otherwise healthy subjects, but
should be given when the Hb is less than 7 g/dl (70 g/l).
K When Hb concentration is less than 7 g/dl (70 g/l) and the patient is otherwise stable,
2 units of red cells should be transfused and the patient’s clinical status and
circulating Hb should be reassessed.
K High-risk patients (465 years and/or those with cardiovascular or respiratory disease)
may tolerate anemia poorly, and may be transfused when Hb concentration is less
than 8 g/dl (80 g/l).
K For Hb concentration between 7 and 10 g/dl (70 and 100 g/l), the correct strategy is
unclear.
When symptoms and signs related to anemia are
present in patients in whom ESA therapy is
ineffective (e.g., bone marrow failure,
hemoglobinopathies, ESA resistance)
K Patients with chronic anemia (e.g., bone marrow failure syndromes) may be
dependent upon red cell replacement over a period of months or years, which can
lead to iron overload.
K Approximately 200mg of iron are delivered per unit of red cells; this iron is released
when Hb from the transfused red cells is metabolized after red cell death.
K Given the progressive loss of red cell viability which occurs during storage, the
‘‘freshest-available’’ units should be selected in order to maximize post-transfusion
survival.
K Hemosiderosis can produce organ damage when the total iron delivered approaches
15 to 20 grams, the amount of iron in 75 to 100 units of red cells.
K The issue of red cell transfusion in patients with acquired or congenital hemolytic
anemia is more complex.
When symptoms and signs related to anemia are
present in patients in whom the risks of ESA therapy
may outweigh the benefits
K ESAs should be used with great caution, if at all, in CKD patients with active
malignancy, a history of malignancy, or prior history of stroke.
CKD, chronic kidney disease; ESA, erythropoiesis-stimulating agent; Hb, hemoglobin.
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could not be calculated for patients listed in 2005. As a result
of the delay in finding compatible donors in patients with
PRA Z80%, the percentage of these patients increased from
7.5% at listing to 13.3% five years after listing.
Not being transplanted, or having to wait longer for
transplantation, is associated with lower survival.228,229
Receiving a transfusion while on the transplant wait list is
associated with a nearly 5-fold higher risk of dying while on
Acute clinical situations 
• Acute severe hemorrhage 
• Unstable coronary artery disease 
• When rapid preoperative Hb correction is 
required 
Chronic clinical situations 
• Chronic anemia and ESAs are ineffective 
(hemoglobinopathies, bone marrow 
failure, ESA resistance) 
Transfuse 
Special chronic clinical situations 
Chronic severe symptomatic anemia and 
a relative contraindication to an ESA 
(e.g., current or previous malignancy, 
previous stroke) 
Potential transplant recipient? 
Yes No
Risk of allosensitization Transfuse 
High Low 
• Previous transplant(s) 
• Previous pregnancies 
• Previous transfusions 
• Untransfused males 
• Untransfused females 
• Nulliparous females 
Assess balance of risks and benefits before transfusing 
Figure 4 |Algorithms for red cell transfusion use in CKD patients. ESA, erythropoiesis-stimulating agent; Hb, hemoglobin.
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the wait list in the first five years, and an 11% reduction in
the likelihood of receiving a transplant within the first five
years.191,230 In transplanted patients, the presence of
preformed HLA antibodies is associated with an increased
risk of early and late graft loss.193,194,231,232 Recent data also
suggest that pre-existing donor-specific HLA antibodies
identified by a Luminex single-antigen assay at the time of
transplantation are associated with a higher incidence of
antibody-mediated rejection and inferior graft survival.233
URGENT TREATMENT OF ANEMIA
4.2: In certain acute clinical situations, we suggest patients
are transfused when the benefits of red cell transfu-
sions outweigh the risks; these include (2C):
K When rapid correction of anemia is required to
stabilize the patient’s condition (e.g., acute
hemorrhage, unstable coronary artery disease)
K When rapid pre-operative Hb correction is
required
RATIONALE
In certain urgent clinical situations, red cell transfusion may
be needed for the immediate correction of anemia. These
include acute severe hemorrhage and other clinical problems
caused by, or exacerbated by, anemia, such as acute
myocardial ischemia. When urgent surgery is required,
transfusion may also be given to achieve rapid preoperative
correction of Hb. The Hb threshold for transfusion in this
situation is uncertain but we suggest that this treatment be
considered if the Hb is o7 g/dl (o70 g/l).
Table 7 and Figure 4 summarize the approaches to the use
of red cell transfusions in patients with CKD.
RESEARCH RECOMMENDATIONS
There is a lack of randomized controlled trials on the use of
blood transfusions as a primary intervention in patients with
anemia and CKD. Given the logistical difficulties in
conducting such trials, it is likely that observational data
will continue to predominate in this therapeutic area.
Future research should include:
K Prospective observational data collection on the use
of red cell transfusions in CKD patients, particularly
dialysis patients, including the reason(s) for transfu-
sion, intent to list for future kidney transplantation,
likelihood of receiving a kidney transplant, and graft
outcomes.
K Prospective observational evaluation of the impact of
red cell transfusions on the level of HLA sensitization.
K Given a striking disparity in the use of blood
transfusions between the US and Europe, Canada
and Australia in the TREAT study, and between the
US and Europe in the Phase 3 peginesatide clinical
trial program, further research is needed to ascertain
the ‘drivers’ for transfusion in CKD patients. Is this
related to practice patterns or a real higher clinical
need for transfusions in the US?
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